Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

56.93 +0.08 (+0.14%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Additional Data From Travere Therapeutics' Kidney Disease Candidate Reinforce Efficacy, Supporting Ongoing Launch ↗

April 03, 2023

Via Benzinga

Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023

April 01, 2023

FILSPARI demonstrated a statistically significant, rapid, and sustained decline of proteinuria compared to the active control

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics to Present at Upcoming Investor Conferences

March 28, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

3 Up-and-Coming Growth Stocks to Buy Right Now ↗

March 25, 2023

These companies are small now but could grow much larger over time.

Via The Motley Fool

Could an FDA Approval Send This Stock Flying? ↗

March 01, 2023

Is now the time to load up on this struggling stock?

Via The Motley Fool

Travere Therapeutics's Return On Capital Employed Overview ↗

February 28, 2023

Via Benzinga

Why Travere Therapeutics Stock Bolted Higher This Week ↗

February 23, 2023

A high-value regulatory approval lit a fire underneath the biotech's shares this week.

Via The Motley Fool

Travere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023

March 23, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

3 Supercharged Stocks Near 52-Week Highs That Could Keep Climbing ↗

March 19, 2023

The high-flyers have soared to new heights and further gains could be up ahead.

Via The Motley Fool

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 14, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics's Earnings Outlook ↗

February 22, 2023

Via Benzinga

What 10 Analyst Ratings Have To Say About Travere Therapeutics ↗

February 22, 2023

Via Benzinga

Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 44th Annual Meeting and the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting 2023

March 14, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

March 03, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

Analyst Views Multiple Opportunities For Chinook To Thrive In Emerging Renal Markets, Sees More Than 100% Upside ↗

March 01, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023 ↗

March 01, 2023

Via Benzinga

Travere Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

February 28, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics Announces Proposed Public Offering of Common Stock

February 27, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

February 23, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

February 21, 2023

Gainers Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023.

Via Benzinga

Earnings Scheduled For February 23, 2023 ↗

February 23, 2023

Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

February 21, 2023

Via Benzinga

Manitowoc, Helix Energy Solutions, JELD-WEN Holding And Other Big Stocks Moving Higher On Tuesday ↗

February 21, 2023

U.S. stocks traded lower, with the Dow Jones dropping around 450 points on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023 ↗

February 21, 2023

Via Benzinga

Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment ↗

February 21, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

February 20, 2023

Via Benzinga

Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy

February 17, 2023

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Travere Therapeutics Announces FDA Accelerated Approval of FILSPARITM (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy

February 17, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results

February 16, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 13, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.